Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Infusion Rituximab in B-Cell Malignancies
NCT01206777Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Oct 2010
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Oct 2010; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01206777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01206777.